Zhu X, Verma S
Department of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON.
Curr Oncol. 2015 Mar;22(Suppl 1):S19-28. doi: 10.3747/co.22.2363.
Breast tumours positive for her2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-her2 therapies has dramatically improved disease control and survival in patients with metastatic her2-positive breast cancer. Targeted agents are now considered the standard of care in the first-line setting and beyond. The present review summarizes the currently available data on targeted anti-her2 therapies from completed randomized phase iii clinical trials and briefly discusses emerging advances that will address unmet needs in metastatic her2-positive breast cancer.
人表皮生长因子受体2（HER2）呈阳性的乳腺肿瘤约占所有乳腺癌病例的20%，并且具有侵袭性的自然病程。靶向抗HER2疗法的出现显著改善了转移性HER2阳性乳腺癌患者的疾病控制和生存率。目前，靶向药物被视为一线及后续治疗的标准疗法。本综述总结了已完成的随机III期临床试验中关于靶向抗HER2疗法的现有数据，并简要讨论了将满足转移性HER2阳性乳腺癌未满足需求的新进展。
